SH
Sabra Health Care REIT, Inc. (SBRA)·Q3 2025 Earnings Summary
Executive Summary
- Q3 2025 delivered solid top-line and SHOP performance: total revenues were $190.0M, GAAP diluted EPS was $0.09, Normalized FFO was $0.36, and Normalized AFFO was $0.38, with SHOP same-store Cash NOI up 13.3% YoY (15.9% ex-Holiday) .
- Versus consensus, revenue beat while EPS missed: Revenue $190.0M vs $188.6M estimate; GAAP EPS $0.09 vs $0.185 estimate; management emphasized normalized FFO/AFFO in line with expectations and guided midpoints maintained for those metrics (EPS/Revenue consensus from S&P Global)* .
- Guidance updated: Normalized FFO/AFFO midpoints unchanged at ~$1.46 and ~$1.50, respectively; GAAP EPS range lowered and AFFO range trimmed; assumptions reaffirmed (G&A ~$50M, cash interest ~$104M, diluted shares ~244.7M/245.7M) .
- Strategy shift accelerates: SHOP concentration target raised to 40% (from 30%), Net Debt/Adj. EBITDA improved to 4.96x, and Moody’s upgraded senior unsecured rating to Baa3; robust acquisition pipeline positions 2026 for stronger contribution .
What Went Well and What Went Wrong
What Went Well
- SHOP momentum: Same-store Cash NOI rose 13.3% YoY (15.9% ex-Holiday) with sequential margin improvement to 28.3%; occupancy trends and REVPOR growth underscore operating leverage .
- Portfolio de-risking and balance sheet strength: Net Debt/Adj. EBITDA fell to 4.96x; cost of permanent debt was 3.94%; Moody’s upgraded to Baa3 with Stable outlook .
- Strategic clarity: CEO raised SHOP concentration target to 40% and expects 2025 investments to exceed prior $500M target; “EBITDARM rent coverage hit another post-pandemic high” across triple-net .
What Went Wrong
- GAAP EPS miss vs consensus amid transition/normalizing items: Q3 GAAP diluted EPS was $0.09 (write-offs and lease termination costs occurred alongside transitions), below S&P EPS consensus*; revenue beat but street focuses on EPS for headline prints .
- Triple-net cash rental income down sequentially: -$3.5M QoQ driven by transitions of four assets to SHOP, asset sales, and normalization of percentage rents .
- Holiday portfolio still a drag within same-store SHOP: management noted lower occupancy in ex-Holiday assets (~80%) weighed on same-store metrics, though stabilization is underway .
Financial Results
Core metrics by quarter (oldest → newest)
Q3 2025 vs prior periods and estimates
Values with asterisks retrieved from S&P Global.
Segment breakdown (Q3 2025, Cash NOI)
KPIs (SHOP and portfolio credit metrics)
Guidance Changes
Assumptions reaffirmed: low-single-digit triple-net Cash NOI growth; mid-teens full-year same-store SHOP Cash NOI growth; no additional tenants moved to cash/accrual basis; only completed transactions included .
Earnings Call Themes & Trends
Management Commentary
- CEO: “Managed senior housing is growing more quickly than anticipated as a percentage of total NOI, and is now roughly 26%. As a result, we are updating our managed senior housing target concentration from 30% to 40%… For Sabra’s triple net portfolio, EBITDARM rent coverage hit another post-pandemic high, with healthy coverage across our top ten tenants.” .
- CFO: “Normalized FFO per share of $0.36 and normalized AFFO per share of $0.38… dividend… represents a payout of 79% of our third-quarter normalized AFFO per share. Net debt-to-adjusted EBITDA is 4.96x… cost of permanent debt was 3.94%… next material maturity 2028.” .
- CIO: “Closed plus awarded deals in 2025 total more than $550 million… Cash NOI and margin were up 18.6% and 90 bps sequentially in the total managed portfolio… occupancy increased 60 bps to 86.8%, and RevPAR rose 4.3% sequentially.” .
Q&A Highlights
- Guidance vs strength: Maintained midpoints for normalized FFO/AFFO despite strong SHOP metrics because most investments close late-year, impacting 2026 more than 2025 .
- Pricing power: With occupancy >90% in Canada, rates rose >5% QoQ; mid-single-digit annual rent increases expected into 2026 as US occupancy rises and supply remains limited .
- Holiday stabilization: Operators right-sized labor; expect additive contribution as stabilization translates into top-line improvement over time .
- Pipeline mix and underwriting: 90–95% of pipeline is SHOP; go-in yields 7–8% with low double-digit levered IRRs; stabilize occupancy in low/mid-90s across markets .
- Balance sheet and ratings: All three agencies at IG; upgrade’s pricing impact modest but validates strategy; leverage-neutral funding via forward equity .
- Strategy on BH: Behavioral health expected to shrink as a share; focus capital on senior housing and skilled nursing .
Estimates Context
- Q3 2025 revenue beat S&P Global consensus ($190.0M actual vs $188.6M estimate); GAAP EPS missed ($0.09 actual vs $0.185 estimate). Management emphasis on normalized FFO/AFFO suggests street models may hold those midpoints steady, with revenue upward bias and GAAP EPS reflecting transition/normalizing items .
- Expect 2026 estimate revisions as late-2025 acquisitions contribute a full run-rate and SHOP margin expansion persists; triple-net coverage strength and reimbursement tailwinds support stability .
Values marked with asterisks retrieved from S&P Global.
Key Takeaways for Investors
- Bold beat on revenue and bold miss on GAAP EPS; focus on normalized FFO/AFFO, which tracked guidance midpoints, and dividend remained well covered (79% of normalized AFFO) .
- SHOP strategy is the growth engine: concentration target raised to 40%, pipeline heavily SHOP, same-store margin now 28.3% with operating leverage from rising occupancy and REVPOR .
- Balance sheet tailwinds: Net Debt/EBITDA at 4.96x, cost of debt 3.94%, next material maturity 2028; Moody’s upgrade strengthens funding flexibility for accretive deals .
- Near-term narrative: Transition/normalizing items and share issuance temper GAAP EPS optics; headline miss can be a trading overhang, but cash-flow metrics and coverage trends are supportive .
- 2026 setup: Late-year closings and awarded deals (> $550M) should drive a fuller run-rate next year; expect estimate revisions to reflect SHOP contribution and margin expansion .
- Risk monitor: Holiday stabilization pace, cap-rate competition, and reimbursement execution; management reiterated no appetite for opco investments and disciplined underwriting yields/IRR .
- Catalysts: Additional SHOP acquisitions, occupancy/rate updates, credit momentum, and continued NOI/margin expansion in SHOP; supplemental disclosures provide granular proof points each quarter .
Citations:
- Q3 press release and 8-K exhibits (financials, guidance, segment metrics) .
- Earnings call transcript (prepared remarks and Q&A detail) .
- Prior quarters for trend analysis (Q1/Q2 results, reimbursement) .
S&P Global estimates: Revenue Consensus Mean ($188.6M)* and Primary EPS Consensus Mean ($0.185)* for Q3 2025; values retrieved from S&P Global.